Sehgal S, Bhattacharya D, Bhardwaj M
WHO Collaborative Centre for Rabies Epidemiology for South-East Asia, National Institute of Communicable Diseases (NICD), Delhi, India.
J Commun Dis. 1994 Sep;26(3):139-46.
Fifty-five individuals bitten by rabid animals were administered purified vero-cell rabies vaccine (PVRV) at WHO Collaborative Centre for Rabies Epidemiology for South-East Asia at National Institute of Communicable Diseases, Delhi to test its immunogenicity, inocuity, safety and clinical efficacy. Fifty-two (94.5 per cent) of these individuals underwent complete course of treatment. Sera samples collected prior to the commencement of treatment showed all these persons to be sero-negative for antibody against Rabies virus. However mean titre of 2.44 I.U./ml, 7.76 I.U./ml and 10.77 I.U./ml were detected after third, fourth and sixth injections, respectively of PVRV. Persistance of protective titres of this antibody could be demonstrated even after 15 months of treatment. Of 327 inoculations, local and general reactions were observed after 10.6 per cent inoculations. All these cases were followed up for periods between 7 and 25 months and were, alive and healthy till the end of observation period, thereby proving the efficacy of the vaccine in preventing rabies.
55名被狂犬咬伤的个体在位于德里的国家传染病研究所的世界卫生组织东南亚狂犬病流行病学合作中心接种了纯化的 vero 细胞狂犬病疫苗（PVRV），以测试其免疫原性、接种性、安全性和临床疗效。其中52人（94.5%）完成了整个疗程。治疗开始前采集的血清样本显示，所有这些人均为狂犬病毒抗体血清阴性。然而，在分别接种PVRV第三针、第四针和第六针后，检测到的平均抗体滴度分别为2.44国际单位/毫升、7.76国际单位/毫升和10.77国际单位/毫升。即使在治疗15个月后，也能证明这种抗体的保护性滴度持续存在。在327次接种中，10.6%的接种后出现了局部和全身反应。所有这些病例均随访了7至25个月，直到观察期结束时均存活且健康，从而证明了该疫苗在预防狂犬病方面的有效性。
